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Abstract
 
Fas ligand (FasL) has been shown to mediate both apoptotic and inflammatory reactions. To
rigorously assess the physiological role of different forms of the FasL molecule with regard to
these two distinct processes, we isolated stably transfected lymphoma cell lines that expressed
either murine wild-type FasL, membrane-only FasL, or functionally distinct forms of soluble
FasL. First, the ability of these lines to induce an inflammatory response was assessed in vivo by
injecting the transfectants intraperitoneally and measuring subsequent neutrophil extravasation
into the peritoneal cavity. Second, lines were assessed by injecting the transfectants subcutane-
ously and monitoring their growth as solid tumors. Our study clearly demonstrated that the
extent of inflammation induced by the transfectants directly correlated with their relative cyto-
toxic activities. A neutrophil response could only be elicited in mice with intact Fas death do-
mains although Fas expression by the neutrophils was not essential. Lymphoma cells expressing
the soluble FasL form corresponding to the natural cleavage product could not trigger apoptosis
and did not induce a neutrophil response. In contrast to the other FasL transfectants, these cells
survived as tumor transplants. However, expression of soluble FasL was not benign, but actu-
ally suppressed the inflammatory response and protected other transfectants from the effector
mechanisms elicted by membrane-bound FasL.
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Introduction
 
Fas ligand (FasL)
 
1
 
 was originally identified as a 40-kD type
II transmembrane protein belonging to the TNF family (1).
Mice that inherit the recessive mutation 
 
gld
 
 lack functional
FasL expression and develop a systemic autoimmune dis-
ease characterized by massive lymphadenopathy, spleno-
megaly, and excessive autoantibody production (2, 3). FasL
expression can be induced on T cells by antigen receptor
engagement and confers the ability to kill Fas
 
1
 
 target popu-
lations (1, 4–6). Coexpression of Fas and FasL by activated
T cells leads to the phenomenon of activation-induced cell
death (7–9). Thus, FasL plays an integral role in the regula-
tion of lymphocyte interactions. FasL can also be constitu-
tively expressed by nonlymphoid cells in the eye and testis,
where its potent proapoptotic activity is thought to con-
tribute to the immune-privileged status of these organs
(10–13). Furthermore, constitutive FasL expression by cer-
tain human and mouse malignant cells may contribute to
immune evasion (14–19).
Based on the presumed ability of FasL to eliminate acti-
vated Fas
 
1
 
 T cells, it was postulated that forced expression
of FasL would protect allografts from lymphocyte-medi-
ated effector mechanisms. A protective effect of FasL was
observed in studies involving melanoma cells (14), myo-
blasts cotransplanted with islet cells (20), and allogeneic co-
lon carcinoma cells (21). However, in other cases, forced
FasL expression was found to facilitate rejection by trigger-
ing a neutrophil-mediated inflammatory response. This
neutrophil-dominated response was observed with a variety
of cell lines and tissues, namely islets (22, 23), myoblasts
(24), or malignant cells (25–28). The circumstances that tilt
the FasL reaction toward silent apoptosis as opposed to
rampant inflammation remain unclear, but may reflect the
extent or form of FasL expression.
Like other members of the TNF family, membrane-
bound FasL can be cleaved from the cell surface to generate
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Abbreviations used in this paper:
 
 CMFDA, 5-chloromethylfluorescein
diacetate; L, ligand; GCSF, granulocyte CSF; HPBS, Hank’s PBS; mFasL,
membrane-only FasL; PEC, peritoneal exudate cell; PWC, peritoneal
washout cell; sFasL, soluble FasL natural cleavage product; sFasL.EX, sol-
uble FasL extracellular domain; wtFasL, wild-type FasL. 
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a 26-kD soluble form (sFasL, 29–33). Soluble TNF-
 
a
 
 is
known to be an important mediator of inflammation (34,
35), whereas membrane TNF-
 
a
 
 mediates cellular cytotox-
icity (36). The role of soluble FasL has been less clear. The
natural cleavage product of human FasL (amino acids 129–
279) was shown to have cytotoxic activity when tested on
extremely sensitive Fas
 
1
 
 populations. Whether this was
physiologically relevant killing is questionable, as human
sFasL does not kill Fas-expressing human Jurkat cells or pri-
mary mouse hepatocytes (30, 37). The equivalent portion
of mouse sFasL (amino acids 127–279) does not appear to
be cytotoxic under any conditions, although a soluble pro-
tein corresponding to the entire extracellular domain of
mouse FasL (amino acids 101–279) has been produced ex-
perimentally and does induce apoptosis (38). Even though
soluble FasL does not efficiently induce apoptosis, it has
been shown to bind Fas and specifically block the apoptotic
activity of membrane-bound FasL (39, 40).
Considerable confusion exists in the literature as to the
relative importance of the membrane and soluble forms of
FasL on the proinflammatory effects of this molecule. It has
been reported that soluble FasL is chemotactic for mouse
and human neutrophils, as assessed by in vitro migration as-
says, consistent with the notion that sFasL can establish a
chemoattractive gradient (41, 42). However, the soluble
FasL reagent used by Ottonello et al. did not represent the
natural FasL cleavage product, but rather corresponded
to the entire extracellular domain of human FasL (42).
Moreover, an IL-1–dependent inflammatory response
was observed when fibrosarcoma cells expressing a mem-
brane-only FasL–CD40L chimeric protein were inoculated
intraperitoneally, suggesting that the membrane form alone
was sufficient to induce neutrophil extravasation (27).
The goal of the current study was to rigorously compare
the proinflammatory capacity of mouse wild-type FasL
(wtFasL), membrane-only FasL (mFasL), soluble FasL (nat-
ural cleavage product, sFasL) and soluble FasL-entire extra-
cellular domain (sFasL.EX) in vivo. We evaluated the abil-
ity of the membrane-bound and soluble forms to induce
and/or inhibit an inflammatory reaction characterized by
neutrophil extravasation into the peritoneum subsequent to
intraperitoneal inoculation of FasL transfectants. The effect
of the different forms of FasL on long term tumor survival
and/or rejection in syngeneic mice was also examined. We
found that the ability of the various transfectants to trigger a
neutrophil response correlated with their apoptotic activity.
Significantly, the natural cleavage product, rather than in-
ducing chemotaxis, actually opposed the activity of mFasL
and protected cells from the neutrophil effector mecha-
nisms.
 
Materials and Methods
 
Mice. 
 
4–5 wk-old female DBA/2J, MRL-
 
lpr
 
, C3H.MRL-
 
lpr
 
, CBA-
 
lpr
 
cg
 
, and CBA/J mice were purchased from The Jack-
son Laboratory. MRL-
 
lpr
 
/
 
gld
 
 mice were bred and maintained at
the Laboratory Animal Science Center, Boston University Medi-
cal Center.
 
Derivation of the Wild-Type, Membrane, Extracellular, and Soluble
FasL Constructs.
 
The full-length wtFasL cDNA was cloned by
reverse transcription-PCR from a T cell hybridoma, 12.13, de-
rived from the fusion of MRL 
 
3 
 
SJL T cells and the BW5147
thymoma cell line. The mouse FasL cDNA was cloned in
pcDNA1 and provided by Dr. D. Panka (Harvard Medical
School). Nucleotide sequencing revealed the cloned FasL cDNA
to be the FasL.1 allotype characteristic of B6, MRL, and SJL mice
(43).
The sFasL construct corresponding to the natural FasL cleavage
product was generated by fusing the mouse granulocyte CSF
(GCSF) signal peptide to the 167–amino acid mouse FasL
ectodomain. The mouse FasL ectodomain was derived by PCR
amplification from pBL-MFLW4, a mouse FasL cDNA that was
cloned from activated C3H splenocytes (2). The pFastBac/mGC-
SFsig-mFasLext plasmid was generated as follows, and was pro-
vided by Steven S. Pullen and Marilyn R. Kehry (Boehringer
Ingelheim Pharmaceuticals, Ridgefield, CT). The 123-bp BamHI–
EcoRI mouse GCSF signal peptide fragment from pGEMT-
mGCSFsig and the 475-bp EcoRI–NotI mFasL ectodomain frag-
ment from pGEMT-mFasLext were coligated into pFastBac1
(GIBCO BRL) digested with EcoRI and BamHI to generate Fast-
Bac-mGCSFsig-mFasLext. For cloning purposes the mGCSFsig-
mFasLext insert was moved into pcDNA3 and pBluescriptSKII
vectors (pcDNA3-sFasL and pSKII-sFasL).
The sFasL.EX was cloned by PCR amplification using the
5
 
9
 
FasL.EX primer (5
 
9
 
-GATTGAATTCCAGCTCTTCCACCT-
GCAGAA-3
 
9
 
) and 3
 
9
 
FasL.EX primer (5
 
9
 
-AATCGCGGCCG-
CTCTTTTAAAGCTTATACAAGCGC-3
 
9
 
) with pcDNA1-
wtFasL as template. The PCR product was EcoRI–NotI digested
and ligated in frame with the mouse GCSF signal peptide of
pcDNA1-mGCSF. For cloning purposes the mGCSFsig-sFasL.EX
insert was moved into pcDNA3 (Invitrogen) and pSKII vec-
tors (Stratagene) (pcDNA3-sFasL.EX and pSKII-sFasL.EX). The
expression plasmids BCMGSNeo-sFasL.EX and BCMGSNeo-
sFasL were generated by subcloning the XhoI–NotI fragment
from pSKII-sFasL.EX and pSKII-sFasL plasmids, respectively, in-
cluding the mouse GCSF secretion signal and either amino acids
106–279 or 126–279 from the mouse FasL into the expression
vector BCMGSNeo, provided by Dr. H. Karasuyama (Tokyo
Metropolitan Institute of Medical Science, Tokyo, Japan). Mouse
wtFasL and the deletion mutant mFasL were also subcloned from
the pSKII cloning vector into the BCMGSNeo expression vector
as XhoI–NotI fragments. The deletion at the FasL metalloprotein-
ase cleavage site was generated by means of recombinant PCR us-
ing pcDNA3-FasL as template. The 5
 
9
 
 portion of FasL cDNA was
amplified using the T7 sense primer containing sequences from
the vector template and the antisense deletion primer asBAH3
(5
 
9
 
-GGGTGTACTGGGGTTGGCCTCACGGAGTTCTGC-
CAG-3
 
9
 
), a sequence coding for amino acids 109–114 and 130–
135 of mouse FasL. The 3
 
9
 
 portion of FasL was amplified using
the sense deletion primer sBAH3 (5
 
9
 
-CTGGCAGAACTCCGT-
GAGGCCAACCCCAGTACACCC-3
 
9
 
), which is complemen-
tary to the antisense deletion primer asBAH3 and the SP6 vector
primer. The primary PCR products containing the 3
 
9
 
 and 5
 
9
 
 por-
tion of FasL, respectively, were purified by agarose gel electro-
phoresis, mixed 1:1, and then amplified by secondary PCR with
T7 and SP6 flanking primers. The EcoRI–XbaI fragment of the
resulting PCR product was cloned into the mammalian expression
vector pcDNA3 and subsequently subcloned as BamHI–XbaI
fragment into the cloning vector pSKII.
 
Cell Lines. 
 
The DBA/2 T lymphoma cell line L5178Y-R
was obtained from the American Type Culture Collection. 
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L5178Y-R as well as LF
 
1
 
, LF
 
2
 
, LB27.4, and Jurkat E6-1 cells
were grown in 10% FCS-RPMI supplemented with 10 
 
m
 
M
Hepes, 50 
 
m
 
M 2-ME, 1
 
3
 
 penicillin/streptomycin/glutamine
(GIBCO BRL). Mouse L5178Y-R T lymphoma cells were
transfected by electroporation with different BCGMSNeo ex-
pression plasmids using the Gene Pulser II (Bio-Rad) with 320 V
and 950 
 
m
 
F in OptiMEM medium (GIBCO BRL). G418-resis-
tant transfectants were selected with 750 
 
m
 
g/ml G418 for 14 d
and cloned twice by limiting dilution to ensure clonality. Trans-
fectant clones expressing different forms of mouse FasL were ei-
ther screened by function (
 
51
 
Cr release of Fas
 
1
 
 target cells), or in
the case of L5-sFasL, by Western blot analysis. At least three
transformed L5178Y-R clones expressing comparable levels of
protein by Western blot or flow cytometry were independently
isolated for each construct. Representative clones were chosen
for further experiments, and designated L5-wtFasL, L5-mFasL,
L5-sFasL.EX, and L5-sFasL. Empty vector–transfected L5178Y-R
cells (L5-neo) were used as control throughout the study.
 
Cytotoxicity Assays. 
 
The cytotoxic activity of the various
L5178Y-R transfectants was quantitated by a 
 
51
 
Cr-release assay,
essentially as described previously (5). LB27.4 is a mouse B lym-
phoma hybridoma (American Type Culture Collection) that ex-
presses mouse Fas and is sensitive to FasL-mediated killing. LF
 
1
 
and LF
 
2
 
 are derived from mouse T lymphoma L1210 cells that
were either transfected with mouse Fas or mouse antisense Fas
such that the former is sensitive and the latter is completely resis-
tant to FasL (44). The transfectants were seeded at different densi-
ties to vary the E/T ratios. After a culture period of 6 h, culture
supernatants were collected and the radioactivity released to the
supernatant was counted with a 
 
g
 
-counter. Labeled cells cultured
in medium alone were used as background controls. The radioac-
tivity released by cells cultured in the presence of 1% NP-40 was
used as a reference for maximum cell death. The specific activity
was determined by the formula: (cpm of experimental sample 
 
2
 
cpm of medium control)/(cpm of maximum release 
 
2 
 
cpm of
medium control).
 
Induction, Isolation, and Characterization of Peritoneal Exudate
Cells.
 
L5178Y-R transfectants (0.6
 
2
 
6 
 
3 
 
10
 
6
 
 cells) were washed
with serum-free Hank’s PBS (HPBS) and injected intraperito-
neally into DBA/2 mice, MRL-
 
gld
 
, MRL-
 
lpr
 
/
 
gld
 
, C3H.MRL-
 
lpr
 
,
CBA-
 
lpr
 
cg
 
, or CBA/J mice. In some experiments, the L5178Y-R
transfectants were preactivated with PMA (300 ng/ml) and iono-
mycin (400 ng/ml) for 4 h and washed extensively with serum-
free HPBS. In some experiments, 5 
 
3 
 
10
 
6
 
 L5178Y-R transfec-
tants were coinjected intraperitoneally into MRL-
 
lpr
 
/
 
gld
 
 mice
together with 6 
 
3 
 
10
 
6
 
 peritoneal washout cells (PWCs) from unin-
duced MRL-
 
1
 
/
 
1
 
 or MRL-
 
lpr
 
/
 
gld
 
 mice. 18 h after tumor inocu-
lation, mice were killed by carbon dioxide asphyxiation. Perito-
neal exudate cells (PECs) were harvested and washed with HPBS
containing 2% FCS. The total number of PECs per mouse was
determined by counting exudate cells with a hemocytometer.
Cytospins of freshly isolated PECs were stained with HEMA 3
stain set (Wright-Giemsa stain; Fisher Scientific). Other aliquots
of fresh PECs were pretreated with 2.4G2, and then stained with
FITC-conjugated anti-Gr1 and PE-conjugated anti-Mac1 or bi-
otinylated anti-Thy1.2 followed by streptavidin-PE (PharMin-
gen), and then analyzed on a FACScan™ flow cytometer (Becton
Dickinson). Acquired data were plotted using CELLQuest™ soft-
ware (Becton Dickinson) with contour plot settings of 10% prob-
ability, smoothing factor 5, and 0.2% threshold.
 
5-chloromethylfluorescein Diacetate Labeling of L5178Y-R Cells.
 
In some experiments, L5-neo and L5-sFasL cells were labeled
with 1 
 
m
 
M 5-chloromethylfluorescein diacetate
 
 (
 
CMFDA, Cell-
Tracker Green; Molecular Probes) before intraperitoneal injec-
tion. Cells were labeled by incubating 2 
 
3 
 
10
 
6 
 
cells/ml at 37
 
8
 
C
for 12 min in prewarmed serum-free medium containing 1 
 
m
 
M
CMFDA. The cells were then washed twice, incubated for an ad-
ditional 1 h in medium at 37
 
8
 
C, and washed two more times.
 
Analysis of Transfectant Membrane and Soluble FasL Expression.
 
FasL expression of full-length and soluble forms of FasL was as-
sessed by Western blot analysis. The L5178Y-R transfectants were
cultured for 24 h in RPMI 1640 containing 1 or 10% FCS at a
concentration of 5 
 
3 
 
10
 
5
 
 cells/ml with or without the metallo-
proteinase inhibitor KB8301 (PharMingen) at a final concentra-
tion of 45 
 
m
 
M. For the last 14 h, PMA (Sigma Chemical Co.) and
inonomycin (Calbiochem) at final concentrations of 300 and 400
ng/ml, respectively, were added to some of the samples as indi-
cated in the Results. Cells were washed with PBS, resuspended in
RIPA buffer that contained a protease inhibitor mix (1
 
3
 
 Com-
plete™; Boehringer Mannheim), and incubated on ice for 20
min. Insoluble material was removed by centrifugation for 10 min
at 12,000 
 
g
 
 and samples were denatured in 1
 
3
 
 Laemmli loading
buffer at 95
 
8
 
C for 5 min. Culture supernatants were concentrated
10-fold with Microcon concentrators (Amicon) with a 10-kD
cutoff membrane (Millipore) and denatured as described above so
that cell lysates and supernatants would correspond to equal cell
equivalents. Protein preparations were separated with 12% SDS-
PAGE gels, transferred onto nitrocellulose membranes (Protran
BA83; Schleicher & Schuell Inc.), and developed using a rabbit
anti–mouse FasL antibody together with an horseradish peroxi-
dase–conjugated anti–rabbit antibody (Santa Cruz Biotechnology)
as secondary antibody. Molecular mass standards (Benchmark pro-
tein markers; GIBCO BRL) were fractionated in parallel, and the
sizes of the standard proteins are shown in kilodaltons.
The rabbit anti-FasL antibody was generated by immunizing
rabbits (Covance) with the peptide C-AminoCaproicAcid-
SEKKEPRSVAHLTGNPHSRS (Research Genetics) that corre-
sponds to the previously used immunogenic peptide 136–155 of
mouse FasL (Elkon, K.B., Hospital for Special Surgery, New
York, NY, personal communication). The peptide was coupled
to Imject
 
®
 
 maleimide-activated KLH (Pierce Chemical Co.) using
the COOH-terminal cysteine.
 
Subcutaneous Tumor Growth. 
 
L5178Y-R transfectants (2 
 
3
 
10
 
6
 
 cells) were washed with serum-free HPBS and injected sub-
cutaneously into the rear flank of syngeneic DBA/2J mice. Tu-
mor growth was followed for up to three weeks by caliper mea-
surements of perpendicular diameters. Mice were killed at earlier
time points if tumor growth exceeded 25 mm.
The effectiveness of bystander rejection was assessed by inject-
ing DBA/2J mice subcutaneously with 2 
 
3 
 
10
 
6
 
 L5-neo cells and
graded numbers of L5-mFasL cells (0.2–2 
 
3
 
 10
 
6
 
) at the same site.
The inhibitory effect of soluble FasL on the bystander rejection
was evaluated by injecting 6 
 
3
 
 10
 
5
 
 L5-mFasL cells subcutaneously
together with 2 
 
3
 
 10
 
6
 
 L5-neo or 2 
 
3
 
 10
 
6
 
 L5-sFasL cells at the
same site.
 
Results
 
Characterization of FasL-expressing L5178Y-R T Lymphoma
Cell Lines.
 
L5178Y-R T lymphoma cells were transfected
with FasL constructs designed to compare the functional
properties of wtFasL (L5-wtFasL), mFasL (L5-mFasL), and
soluble FasL. Soluble forms of FasL were generated by fus-
ing the mouse GCSF signal peptide with the 187–amino
acid sFasL.EX (L5-sFasL.EX) or the 167–amino acid FasL 
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natural cleavage product ectodomain, sFasL (L5-sFasL) (Fig.
1), to facilitate the exclusive production of soluble proteins
(30, 36). Empty vector (BCMGSneo)-transfected (L5-neo)
cells routinely served as controls.
The cytotoxic activity of the distinct FasL forms ex-
pressed by stably transfected L5178Y-R cells was assessed
by 
 
51
 
Cr release. Three independently isolated transfected
clones were analyzed per group, except for L5-neo where a
pool of G418-resistant cells was used. L5-mFasL cells killed
Fas
 
1
 
 LB targets (Fig. 2 A) much more effectively then L5-
wtFasL. Cytotoxicity in this assay was Fas dependent, as
neither the parental L5178Y-R cells nor the L5-neo cells
were able to kill the target population. Furthermore, the
FasL-transfected cells also killed the Fas
 
1
 
 LF
 
1
 
 line, but not
the Fas
 
2
 
 cell line LF
 
2
 
 (data not shown). Compared with
L5-wtFasL and L5-mFasL, the L5-sFasL.EX cells were only
weakly cytotoxic in this type of assay, where effector activ-
ity during the 6-h assay was compared on a per cell basis.
Cells expressing the construct corresponding to the natural
cleavage product, L5-sFasL, were not cytotoxic. Activation
of the transfected lines with PMA and ionomycin increased
the level of expression of the transfected constructs reflected
by an increase in the cytotoxic activity of all of the FasL
forms except sFasL. Even at high concentrations, the L5-
sFasL cells did not kill our most sensitive target population
(Fig. 2 B).
 
mFasL Is Not Cleaved from the Cell Surface of L5178Y-R
Cells.
 
The enhanced cytotoxic activity of the L5-mFasL
transfectants was consistent with the assumption that these
Figure 1. Constructs used for the analysis of the mouse FasL metallo-
proteinase cleavage site. The structures of the wtFasL and mFasL are sche-
matically drawn to scale. CYT, TM, and EXT represent the cytoplasmic,
transmembrane, and extracellular regions of mouse FasL, respectively.
Filled stars indicate the sites that correspond to the metalloproteinase
cleavage sites reported for human FasL. The metalloproteinase site mutant
was generated by deleting the region around the cleavage site D115-129.
mGCSF represents the secretion signal of mouse GCSF that was fused in
frame with the extracellular region of mouse FasL in case of the sFasL.EX
and sFasL constructs.
Figure 2. Characterization of
FasL-expressing L5178Y-R thy-
mic lymphoma cell lines. (A and
B) Cytotoxic activity of FasL
constructs.  51Cr-labeled LB tar-
gets were mixed with unacti-
vated (A) or PMA plus ionomy-
cin–preactivated (B) L5178Y-R
transfectants and cultured at 378C
for 6 h. Spontaneous release was
,20%. Values shown represent
the mean of triplicate wells; SD
was  ,5%. One representative
experiment of three comparable
assays is shown. (C) The metallo-
proteinase inhibitor KB8301 in-
creased cellular FasL expression
levels of wtFasL but not mFasL.
L5-neo, L5-wtFasL, or L5-
mFasL cells were cultured for 24 h
in 10% FCS/RPMI medium in the presence or absence of the metalloproteinase inhibitor
KB8301 (45 mM) as indicated. 300 ng/ml PMA and 400 ng/ml ionomycin (P1I) were added
to some of the samples for the last 14 h of culture. (D) L5-mFasL cannot be cleaved by the
metalloproteinase to produce sFasL. Cell lysates (abbreviated as C) and 10-fold concentrated
culture supernatants (abbreviated as S) from PMA plus ionmycin–stimulated cells were ana-
lyzed by Western blotting using a rabbit anti–mouse FasL antibody. 
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cells expressed a higher level of FasL protein on their sur-
face. To better demonstrate that the 
 
D
 
115–129 deletion ef-
fectively removed the presumed metalloproteinase cleavage
site, the L5-wtFasL and L5-mFasL cells were further exam-
ined by Western blot analysis. Cell lysates from unactivated
and PMA 1 ionomycin-activated L5-neo, L5-wtFasL, or
L5-mFasL cells were obtained. PMA and ionomycin acti-
vation induced cellular FasL expression in L5-wtFasL and
L5-mFasL cells with an apparently higher steady state level
in L5-mFasL cells than in L5-wtFasL cells (Fig. 2 C). A
24-h culture period with the metalloproteinase inhibitor
KB8301 had no effect on the expression level of mFasL,
but increased the level of cell-associated wtFasL. This indi-
cates that although wtFasL is synthesized at the same rate as
mFasL in the selected L5178Y-R clones, constitutive me-
talloproteinase activity diminished cell surface expression of
the wild-type protein. Concentrated culture supernatants
from PMA plus ionomycin–stimulated L5-neo, L5-wtFasL,
L5-mFasL, L5-sFasL.EX, and L5-sFasL cells were also ob-
tained. Inhibition of cell surface cleavage in the case of
mFasL was confirmed by a lack of soluble FasL in the cul-
ture supernatant of L5-mFasL clones. The 26 kD soluble
FasL fragment could be detected in culture supernatant of
L5-wtFasL cells (Fig.2 D) but not when L5-wtFasL cells
were cultured in the presence of the metalloproteinase in-
hibitor KB8301 (data not shown). Soluble products could
also be detected in the cell culture supernatants from L5-
sFasL.EX and L5-sFasL. The diffuse bands probably result
from variable glycosylation of the transfected protein prod-
ucts (Fig. 2 D).
Wild-type, Membrane, and sFasL.EX Are Proinflammatory,
but sFasL Is Not Proinflammatory. The panel of FasL trans-
fectants allowed us to rigorously compare the proinflamma-
tory properties of membrane and soluble FasL by monitor-
ing the effects of the transfectant inoculation in an in vivo
setting. DBA/2 mice were injected intraperitoneally with
6 3 105 syngeneic L5178Y-R lymphoma cells transfected
with either mFasL, wtFasL, sFasL, sFasL.EX, or empty vec-
tor. PECs were recovered 16 h later. L5-mFasL cells in-
duced a strong inflammatory response characterized by a
massive neutrophil infiltration into the peritoneum, as
shown by the dramatic increase in the percentage of Mac1/
Gr1 double positive cells (Fig. 3 A), as well as in the total
number of neutrophils that could be collected from the
Figure 3. wtFasL, mFasL, and
sFasL.EX were proinflammatory;
sFasL was not proinflammatory.
Sex- and age-matched DBA/2
mice were injected intraperito-
neally with either 6 3 105
L5178Y-R unactivated transfec-
tants, or 2 3 106 L5178Y-R
transfectants that had been preac-
tivated for 4 h with PMA plus
inonomycin as indicated. 16 h
later, PECs were recovered from
peritoneal cavities. (A) Cells
were stained with PE-conju-
gated anti-Mac1 and FITC-con-
jugated anti-Gr1 antibodies, and
analyzed by flow cytometry. (B)
The total number of neutrophils
per mouse was calculated by
multiplying the percentage of
Mac1/Gr1-positive cells with
the total number of PECs recov-
ered. Data represent the mean of
two to three mice in each group.
(C) Cytospin preparations of
PECs obtained from mice in-
jected with the indicated trans-
fectants were stained with
Wright-Giemsa staining solu-
tion to identify polymorphonu-
clear leukocytes. Experiments
were repeated in variation three
times with similar results.1214 Opposing Effects of Transmembrane and Soluble FasL
peritoneal cavity (Fig. 3 B). PECs were also morphologi-
cally examined by staining cytospin preparations of the
peritoneal washout preparations with a Wright Giemsa
stain (Fig. 3 C), and an increased number of polymorpho-
nuclear cells correlated with the flow cytometric results. All
of the actively cytotoxic forms of FasL, namely mFasL, wt-
FasL, and sFasL.EX, induced inflammation; mFasL was the
strongest inducer and wtFasL and sFasL.EX were some-
what less effective. Comparable results were also obtained
with mFasL, and with empty vector–transfected WR19L
lymphoma cells that were inoculated intraperitoneally into
syngeneic BALB/c mice (data not shown). Significantly,
the cytotoxic inactive natural cleavage product, sFasL,
never induced a greater response than the L5-neo control
population even when high numbers of cells (2 3 106)
were injected and/or when sFasL expression was upregu-
lated by PMA and ionomycin preactivation (Fig. 3 B).
These data demonstrate that both the cytotoxic and the
proinflammatory effects of FasL are mediated by the trans-
membrane form of FasL. Nevertheless, membrane expres-
sion is not required, as sFasL.EX is able to induce neutro-
phil inflammation in this system.
Inflammation Depends on Death Domain–intact Recipient
Fas Expression. Although L5-neo cells were used as con-
trols throughout the study, it was important to confirm
that the observed effect was truly Fas dependent. MRL-gld
and double mutant MRL-lpr/gld mice were inoculated in-
traperitoneally with 5 3 106 L5-neo or L5-mFasL cells.
After 16 h, PECs were isolated and analyzed, as described
in Fig. 3 C. Only mice with functional Fas expression
(MRL-gld) were able to mount a neutrophil response.
MRL-lpr/gld mice were completely resistant to high num-
bers of L5-mFasL cells (Fig. 4 A).
Recent studies involving an in vitro migration assay in-
dicated that FasL-mediated chemotaxis was independent of
the death domain of the Fas receptor (41). To reexamine
this issue in vivo, CBA-lprcg mice, known to express Fas
molecules with a nonfunctional Fas death domain (45),
were challenged intraperitoneally with 5 3 106 L5-neo or
L5-mFasL cells. CBA/J and C3H.MRL-lpr mice were used
as Fas1 and Fas2 control recipients. FasL-induced neutro-
phil inflammation was clearly shown to depend on the in-
tact Fas receptor death domain, as L5-mFasL cells failed to
elicit neutrophil extravasation in either C3H.MRL-lpr or
CBA-lprcg mice while the response in CBA/J mice was
comparable to that observed in DBA/2J mice (Fig. 4 B).
Surface Fas expression was confirmed by staining isolated
thymocytes from C3H.MRL-lpr, CBA-lprcg, and CBA/J
mice with the mAb Jo-2 (Fig. 4 C). As expected, CBA-
lprcg and CBA/J showed comparable Fas surface expression,
whereas C3H.MRL-lpr mice had greatly diminished levels
of Fas. Consistent with previous reports (46), isolated thy-
mocytes from both C3H.MRL-lpr and CBA-lprcg mice
were completely resistant to FasL-mediated apoptosis (Fig.
4 D).
PWCs from MRL-1/1 Mice Restore FasL-mediated Neu-
trophil Inflammation in MRL-lpr/gld Mice. Functional re-
cipient Fas expression is necessary for mounting a neutro-
phil response to FasL. As a soluble FasL gradient is highly
unlikely to establish a neutrophil-chemoattractive gradient
in vivo, we hypothesized that the initial apoptotic/proin-
flammatory event in the peritoneum is Fas dependent and
Figure 4. Inflammation depends on re-
cipient death domain–intact Fas expression.
(A) MRL-gld and MRL-lpr/gld mice were
injected intraperitoneally with 5 3 106 L5-
neo or L5-mFasL cells. After 16 h, PECs
were prepared and analyzed as described in
the legend to Fig. 3. Shown is one repre-
sentative experiment out of two; bars rep-
resent the mean of three mice per group,
and error bars represent the SD. (B)
C3H.MRL-lpr, CBA-lprcg, and CBA/J mice
were injected intraperitoneally with 5 3 106
L5-neo or L5-mFasL cells. After 16 h, PECs
were prepared and analyzed as described in
the legend to Fig. 3. The total number of
neutrophils per mouse was compared be-
tween different groups. Data represent the
mean of two mice per group, and error bars
represent the SD. (C) Isolated thymocytes
from C3H.MRL-lpr, CBA-lprcg, and CBA/J
mice were stained for Fas surface expression
with the mAb Jo-2. (D) The sensitivity of
thymocytes from C3H.MRL-lpr, CBA-
lprcg, and CBA/J mice to FasL-mediated
killing was assessed. In brief, isolated thy-
mocytes were 51Cr labeled and used as tar-
gets in a 6-h cytotoxic assay with L5-mFasL
as effector cells. Target thymocytes were
mixed with L5-mFasL cells at E/T ratios
ranging from 12:1 to 0.3:1 and incubated
for 6 h.1215 Hohlbaum et al.
the subsequent neutrophil extravasation is Fas independent.
MRL-lpr/gld mice were coinjected with 5 3 106 L5-
mFasL or L5-neo cells and 6 3 106 PWCs from uninduced
MRL-1/1 or MRL-lpr/gld mice. The percentage of neu-
trophils in the PWCs from uninduced MRL-1/1 or
MRL-lpr/gld mice that were used to reconstitute the re-
sponse in MRL-lpr/gld mice was ,2% (data not shown).
MRL-lpr/gld neutrophils extravasated into the peritoneum
only in response to L5-mFasL cells plus PWCs from MRL-
1/1 mice and did not respond to L5-neo cells plus MRL-
1/1 PWCs or L5-mFasL cells plus MRL-lpr/gld PWCs
(Fig. 5).
sFasL Inhibits the Proinflammatory Activity of mFasL. Sol-
uble FasL has been isolated from cell culture supernatants as
a stable trimer that can bind to the Fas receptor (40) and at
high doses is able to inhibit the cytotoxic activity of mFasL
(39). To determine whether sFasL could also block the
proinflammatory activity of mFasL, we evaluated the ability
of L5-sFasL to protect tumor cells from mFasL-triggered
rejection. L5-sFasL and L5-neo cells were labeled in vitro
with CMFDA and then inoculated intraperitoneally into
DBA/2/J mice either alone or together with L5-mFasL
cells. Labeling L5-sFasL and L5-neo cells allowed us to
readily monitor their persistence in the adoptive host.
From preliminary experiments with unlabeled cells, we had
noted that L5-mFasL cells persisted significantly less well
than either L5-sFasL or L5-neo cells. When 2 3 106 CM-
FDA-labeled L5-neo cells were mixed with 6 3 105 L5-
mFasL cells, the survival of the L5-neo cells was diminished
relative to survival in mice injected with CMFDA-labeled
L5-neo cells alone (Fig. 6 A). The decreased survival was
presumably due to bystander killing (26). In contrast, the
survival of CMFDA-labeled L5-sFasL cells was not com-
promised in mice coinjected with L5-mFasL cells. This in-
dicates that sFasL has a protective antiinflammatory effect.
This interpretation was also supported by a decrease in the
percentage of peritoneal neutrophils seen in cytospin prep-
arations from mice that were injected with a combination
of L5-mFasL and L5-sFasL, compared with mice that were
injected with a combination of L5-mFasL and L5-neo (Fig.
6 B).
To assess the effect of the FasL constructs on long-term
L5178Y-R tumor growth, DBA/2 mice were injected
subcutaneously in the flank with 2 3 106 L5-neo, L5-
mFasL, L5-sFasL.EX, or L5-sFasL cells, and tumor growth
was evaluated over a period of 3 wk. As expected with syn-
geneic transplants, parental L5178Y-R or L5-neo cells
grew as solid tumors in DBA/2 mice (Fig. 7 A). However,
Figure 5.  PWCs from MRL-1/1 mice restore FasL mediated neu-
trophil inflammation in MRL-lpr/gld mice. PWCs from untreated
MRL-1/1 and MRL-lpr/gld mice were prepared as described and coin-
jected intraperitoneally with L5-mFasL or L5-neo cells into MRL-lpr/gld
mice. After 16 h, PECs were prepared and analyzed as described in the
legend to Fig. 3 A.
Figure 6.  Soluble FasL inhibited the proinflammatory activity of
mFasL. (A) DBA/2 mice were injected intraperitoneally with either 2 3
106 PMA plus ionomycin–preactivated or 6 3106 unactivated, CMFDA-
labeled L5-neo, or CMFDA-labeled L5-sFasL cells alone, or as a mixture
with 6 3 105 L5-mFasL cells. After 16 h, PECs were isolated and survival
of the CMFDA labeled tumor cells was assessed by flow cytometry. The
relative rate of tumor cell survival was calculated by dividing the number
of cells recovered, when L5-sFasL and L5-neo cells were mixed with L5-
mFasL, by the number of cells recovered when L5-sFasL and L5-neo cells
were injected alone. Shown are the pooled results from two independent
experiments; dots represent relative survival rates of labeled tumor cells
per mouse. (B) Neutrophil inflammation was assessed by blind enumera-
tion of the number of neutrophils per 100 PECs in Wright-Giemsa–
stained cytospins. A representative field is shown for each group. The
number in the top right corner indicates the mean percentage of neutro-
phils 6 SD of three to four mice per group.1216 Opposing Effects of Transmembrane and Soluble FasL
due to the proinflammatory properties of membrane FasL,
L5-mFasL cells were rejected and no tumor growth was
observed, even after an extended period of time (2 mo) as
has previously been shown for human and mouse wtFasL
(26). Tumor progression of the L5-sFasL cells was similar
to the parental and L5-neo cells, confirming their inability
to trigger an inflammatory response. Interestingly, L5-
sFasL.EX cells were not rejected although delayed growth
kinetics were observed.
To assess whether the antiinflammatory effect of sFasL
observed in the peritoneum would influence long term
subcutaneous tumor growth, the bystander rejection of
FasL2 cells coinjected with FasL-expressing cells was reex-
amined. DBA/2 mice were subcutaneously inoculated with
a mixture of L5-neo and L5-mFasL cells. mFasL effectively
mediated bystander killing of FasL2 lymphoma cells at ra-
tios of 1:1 and 1:3 (Fig. 7 B) comparable to the bystander
rejection observed with human wtFasL (26). To assess
whether soluble FasL is able to inhibit bystander killing, a
mixture of 2 3 106 L5-sFasL or L5-neo cells was inocu-
lated together with 6 3 105 L5-mFasL cells. The mixture
of L5-mFasL and L5-neo cells was again rejected, whereas
L5-sFasL inhibited the proinflammatory activity of L5-
mFasL and thus allowed for tumor outgrowth (Fig. 7 C).
Discussion
Several of the TNF family members are type II mem-
brane proteins that can be cleaved by metalloproteinases to
release soluble protein segments. The soluble form of
TNF-a is a potent inflammatory agent (34, 35), soluble
CD40L (47) induces B cell proliferation and IgE synthesis
in conjunction with IL-4 (48), and soluble B cell activating
factor (BAFF) costimulates B cells (49). Thus, it might have
been expected that soluble FasL would also have functional
activity. Early reports indicated that the natural cleavage
product of human sFasL did have cytotoxic activity (30),
albeit relatively weak activity compared with the mem-
brane form (37). The natural cleavage product of mouse
FasL was reported to be even less cytotoxic (30), although
an artificial construct corresponding to the entire extracel-
lular domain was found to induce significant levels of apop-
tosis (38). These observations suggested that extracellular
residues 101–125 of mouse FasL might facilitate the oligo-
merization of Fas trimers necessary for efficient activation
of the caspase cascade (40). The data also suggested that the
most significant outcome of FasL cleavage was to attenuate
the potent apoptotic activity of the membrane form. This
assumption is at least partially valid, since as shown previ-
ously (37), and in this study, cells stably transfected with the
membrane-only form of FasL kill much more effectively
on a cell for cell basis than cells transfected with the con-
struct corresponding to wild-type protein.
Separate from its apoptotic activity, the forced expres-
sion of FasL in several cell types has been shown to induce
an effusive neutrophil-mediated inflammatory response, as
documented in vivo by either tissue transplant infiltration
(22–26, 28, 50, 51) or neutrophil extravasation to the peri-
toneal cavity (27). In vitro studies involving Boyden cham-
ber migration assays suggested that the neutrophil response
could be triggered by the establishment of a sFasL
chemoattractant gradient (41, 42). We felt it was important
Figure 7.  mFasL-induced bystander rejection of subcutaneous tumors
was inhibited by sFasL. (A) Subcutaneous tumor growth of L5 transfec-
tants. DBA/2 mice were injected subcutaneously with 2 3 106 L5-neo,
L5-mFasL, L5-wtFasL, L5-sFasL.EX, or L5-sFasL cells and tumor size
was measured periodically with a caliper. Data from two independent ex-
periments were pooled, bars represent mean tumor size at day 11 of six to
eight mice per group, and error bars represent the SD. (B) Bystander re-
jection of L5-neo but not L5-sFasL cells coinjected with L5-mFasL cells.
DBA/2 mice were subcutaneously inoculated with a mixture of L5-neo
and L5-mFasL cells. The number of L5-neo cells was kept constant at 2 3
106 cells, and L5-mFasL cells were graded from 2 3 106 to 2 3 105 cells.
Tumor size was measured periodically with a caliper for 2 wk. Data rep-
resent the mean of two mice per group 6 SD. Soluble sFasL inhibits by-
stander rejection. DBA/2 mice were subcutaneously inoculated with a
mixture of 6 3 105 L5-mFasL cells and either 2 3 106 L5-neo or L5-
sFasL cells. 6 3 105 L5-mFasL cells, 2 3 106 L5-neo, or 2 3 106 L5-sFasL
cells were also inoculated alone as controls. Tumor growth was followed
for 3 wk. Data from two independent experiments were pooled, bars rep-
resent mean tumor size at day 11 of six to nine mice per group, and error
bars represent the SD.1217 Hohlbaum et al.
to reexamine the role of sFasL in an in vivo system where
we could rigorously compare the functional effects of the
various FasL products. L5178Y-R T lymphoma cells were
stably transfected with constructs that allowed for the dis-
crete expression of wtFasL, mFasL, a secreted form of the
natural cleavage product, or the secreted form of the entire
extracellular domain. Our data clearly demonstrated that
the proinflammatory activity of FasL could be mediated by
FasL that was solely membrane-bound and thus neutrophil
extravasation did not depend on the establishment of an
sFasL chemoattractive gradient. Moreover, the extent of
inflammation seemed to correlate with the potential to in-
duce apoptosis, as sFasL.EX is proapoptotic, especially
when the level of expression was increased by PMA and
ionomycin, and it is also proinflammatory. Previous data
indicating that a soluble FasL reagent, corresponding to the
sFasL.EX construct, chemoattracted human neutrophils in
an in vitro chemotaxis assay might simply reflect direct (or
indirect) effects of a proapoptotic sFasL on neutrophil acti-
vation (42).
The direct link between apoptosis and inflammation was
further supported by the experiments in lprcg mice, where it
was unequivocally shown that an intact Fas death domain
had to be expressed by the host for an inflammatory re-
sponse to ensue. Thus, the initial event leading to an in-
flammatory response is likely to be the apoptotic demise of
a Fas-expressing target population, contrary to the assump-
tion that apoptotic death does not lead to inflammation.
We surmise that cytokines or chemokines released by cer-
tain target cells (in this case, neutrophils or other resident
peritoneal cells) are then the key factor in promoting subse-
quent inflammation. Previous studies have demonstrated
that FasL-mediated apoptosis is not necessarily a passive
process, but that dying cells can release functionally signifi-
cant levels of IL1 (27) or IL-10 (52).
Although neutrophils have been shown to express Fas, it
was not clear whether neutrophils per se must express Fas in
order to extravasate in a FasL-triggered inflammatory re-
sponse. To address this question, we injected Fas-deficient
MRL-lpr/gld mice with a combination of L5-mFasL cells
and PWCs from unmanipulated mice. The peritoneal
washout populations per se contained very few neutrophils.
Nevertheless, the combination of L5-mFasL and MRL-1/1
PWCs resulted in significant extravasation to the perito-
neal cavity of neutrophils derived from the Fas-deficient
host. The combination of L5-mFasL and MRL-lpr/gld
PWCs did not induce neutrophil extravasation, indicating
that the neutrophil response was not simply due to nonspe-
cific inflammation. These results support a model in which
FasL triggering of a target population, not necessarily a neu-
trophil, can lead to the release of factors chemoattractive for
neutrophils, such as IL-1 (27). Experiments are in progress to
further identify the relevant target population(s). It will
be important to determine whether the Fas2 neutrophils
induced to extravasate by the MRL-1/1 PWCs are func-
tionally equivalent to the Fas1 neutrophils induced in the
original protocol. It is possible that activation via Fas may
be regulated independently of extravasation.
Activated neutrophils have a powerful arsenal of effector
mechanisms, mainly phagocytosis and formation of hydro-
lytic enzymes and reactive oxygen products, to eradicate
FasL-expressing tumor cells (53). In an in vitro cytotoxic
assay, it was shown that Fas1 neutrophils preferentially
killed FasL-expressing targets over FasL2 control cells (26,
50). Either Fas–FasL interactions simply facilitate intimate
cell contact that enhances the delivery of cytolytic factors,
or reverse signaling through FasL somehow contributes to
cytolytic events. Our data, demonstrating that L5-sFasL.EX
cells induced neutrophil inflammation in the peritoneum
even though L5-sFasL.EX cells were not rejected as effi-
ciently as L5-mFasL tumor cells supports the conclusion
that Fas/FasL-facilitated cell contact promotes the elimina-
tion of the FasL-expressing effector cells.
In contrast to the soluble product corresponding to the
entire extracellular domain, the natural cleavage product
failed to induce even the slightest indication of an inflam-
matory response. The exact biochemical characteristics of
the two molecules that account for this difference are not
clear. Previous studies have shown that sFasL exists as ho-
motrimers, as it was reported that sFasL.EX (WX1) can ex-
ist as higher order oligomers (38, 40). It may be that the 15
amino acids present in the sFasL.EX were involved in mul-
timerization of FasL in solution or on the target cell sur-
face. Nevertheless, the L5-sFasL cells were functionally dis-
tinct from the vector control L5-neo cells, as shown in
bystander assays. Although a previous report has shown that
neutrophils specifically killed FasL-expressing targets and
not control cells (26, 50), we found that bystander L5-neo
cells, but not L5-sFasL cells, were specifically eliminated by
an L5-mFasL–induced neutrophil response. In the latter
group, the L5-sFasL antiinflammatory effect was further
demonstrated by the reduced number of neutrophils that
extravasated to the peritoneum of these mice. The antiin-
flammatory effect of sFasL was also apparent in the more
long term experiments monitoring progression of subcuta-
neously injected tumor cells. Here, it was found that the
proinflammatory effects of the L5-mFasL cells prevented
the outgrowth of coinjected L5-neo cells, but that the anti-
inflammatory sFasL worked in opposition to the mFasL and
allowed for the outgrowth of coinjected L5-sFasL cells.
Binding of sFasL to the Fas receptor may simply block
mFasL engagement or it may provide an antiapoptotic sig-
nal. Membrane expression might allow for more extensive
oligomerization of FasL trimers or it might retain the Fas
receptor complexes on the cell surface and thus allow for
more efficient activation of the caspase cascade.
Several examples can now be found in the literature of
situations in which FasL-expressing APCs can effectively
eliminate antigen-specific T cells without evidence of in-
flammation (54, 55). Whether the outcome of apoptotic
death is silent or whether it leads to inflammation must de-
pend on several factors, including the level of metallopro-
teinase-released sFasL activity as well as the levels of other
apoptotically induced chemokines and cytokines.1218 Opposing Effects of Transmembrane and Soluble FasL
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